YK-11
Hybrid SARM/myostatin inhibitor — strong anecdotal hypertrophy.
Evidence
anecdotal
Legal status
research only
Half-life
~6-10 hours
Routes
oral
What it is
YK-11 is technically a SARM but has the unusual feature of inducing follistatin expression, giving it a dual anabolic mechanism. Human data is essentially nil.
Mechanism
Selective androgen receptor partial agonist that upregulates follistatin.
Outcomes it's matched to
- STRENGTH70%
Safety
Possible hepatotoxicity and HPTA suppression.
- Liver disease
- Pregnancy
Legal context
Research use only. WADA-prohibited.